Skip to main content
Fig. 3 | Renal Replacement Therapy

Fig. 3

From: Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study

Fig. 3

Changes in mean hemoglobin levels (line graph with closed circles) following a switch from erythropoietin treatment in a patients not on dialysis, b patients on hemodialysis, and c patients on peritoneal dialysis. Bar graph represents mean dose of continuous erythropoietin receptor activator (CERA) administered; error bars represent ± 1 standard deviation

Back to article page